SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026

The updated clinical data report durable responses and a favorable tolerability profile in heavily pretreated participants with HER2-driven cancers.

IAM

Related stories